Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Executive Summary

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.

Advertisement

Related Content

Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan Sees Growth From New Launches, Not Big M&A
Allergan's Fishing For Deals, But Don't Expect A Big Catch
Beyond Tax Benefits: Portfolio Opportunities In A Pfizer-Allergan Deal
Actavis will become Allergan to emphasize branded pharma focus
Forest gaining 'relevant' GI position with Furiex buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel